Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

Inclusion Criteria: * Patients must give written informed consent before any assessment is performed. * Subject has moderate-to-severe HS as defined by: 1. HS lesions in at least 2 distinct anatomic areas, one of which is Hurley stage II or III on evaluation at Screening. 2. Stable HS for at least 2 months (60 days) prior to Screening and also at the Baseline visit as determined by the investigator. * Total abscess and inflammatory nodule (AN) count of greater than or equal to 3 at the Baseline visit. * Subject has had HS diagnosis for at least 3 months prior to Baseline. * Subject must have failed at least one prior course of oral antibiotics. * Subject must agree to daily use (and throughout the entirety of the study) of one of the following over-the-counter topical antiseptics on their body areas affected with HS lesions: chlorhexidine gluconate, triclosan, benzoyl peroxide, or dilute bleach in bathwater. * Subject must be at least 18 years of age at time of Screening Exclusion Criteria: * Subject has had history of malignancy within the past 5 years * Women who are pregnant, nursing, or planning pregnancy within 6 months after last subcutaneous injection. Male patients who are planning for their partner's pregnancies within 6 months from the last subcutaneous injection * Subject has history of active TB. Subjects with latent TB must have been on treatment for at least 8 weeks prior to Baseline visit and the course of prophylaxis is planned to be completed. * Subject has had infections requiring oral or intravenous (IV) antibiotics within 14 days prior to Baseline. * Subject has significant serious medical problems or a condition that significantly immunocompromises the subject. * Subject has had clinically significant hematological abnormalities defined as HGB \<13.5 g/dL (\<135 g/L) or a HCT \<41.0 percent in men, or a value \<12.0 g/dL (\<120 g/L) or \<36.0 percent in women. * Subject has previously used secukinumab. * Subject has had any other active skin disease or condition that may interfere with HS assessment. * Subject has received prescription topical therapies for treatment of HS within 7 days prior to Baseline. * Subject has received systemic non-biologic therapies with potential therapeutic impact for HS \<14 days prior to Baseline visit. * Clinically significant abnormal laboratory values as evaluated by the investigator. * Patients with Crohn's disease or Ulcerative Colitis. * Subject has received any systemic immunosuppressive treatment within 1 month prior to Baseline visit. Subject has received anti-TNF therapy within 3 months prior to Baseline visit. Subject has received anti IL-23 therapy within 3 months prior to Baseline visit. * Subject has received intralesional steroid injection within 2 weeks prior to Baseline visit. * Subject with known Human Immunodeficiency Virus (HIV) positive status or with positive HIV testing at Screening. * Subjects with Hepatitis B and Hepatitis C positive status or with positive Hepatitis B and Hepatitis C testing at screening. * Subjects with active cardiovascular disease or relevant risk factors such as prior myocardial infection or stroke. * Subjects with chronic infection or a history of recurrent infections. * Subjects with a history of latex allergy or sensitivity.